ExodusPoint Capital Management’s Maravai LifeSciences MRVI Stock Holding History

ExodusPoint Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-395,547	Closed	-$3.43M	–	1809
2024 Q1	$3.43M	Buy	+395,547	New	+$2.68M	0.03%	516
2023 Q3	–	Sell	-231,484	Closed	-$2.88M	–	1975
2023 Q2	$2.88M	Buy	+231,484	New	+$3.12M	0.02%	662
2023 Q1	–	Sell	-146,667	Closed	-$2.1M	–	1996
2022 Q4	$2.1M	Buy	+146,667	New	+$2.31M	0.03%	615
2022 Q3	–	Sell	-51,924	Closed	-$1.48M	–	2144
2022 Q2	$1.48M	Sell	51,924 -41,840	-45%	-$1.33M	0.02%	915
2022 Q1	$3.31M	Buy	93,764 +85,230	+999%	+$2.86M	0.04%	554
2021 Q4	$358K	Buy	+8,534	New	+$346K	﹤0.01%	1588
2021 Q3	–	Sell	-20,729	Closed	-$865K	–	2446
2021 Q2	$865K	Sell	20,729 -608	-3%	-$23.6K	0.01%	1077
2021 Q1	$760K	Sell	21,337 -6,313	-23%	-$209K	0.01%	1085
2020 Q4	$776K	Buy	+27,650	New	+$770K	0.01%	993

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ExodusPoint Capital Management's MRVI Position: Q2 2024 in Review

ExodusPoint Capital Management sold out of Maravai LifeSciences (MRVI) in Q2 2024, closing a stake of 395,547 shares — an estimated $3.43M sold.

ExodusPoint Capital Management first reported a position in MRVI in Q4 2020 and held it in 9 quarters. The position peaked at $3.43M in Q1 2024. 206 funds tracked by Wall St. Rank hold MRVI as of Q2 2024.

ExodusPoint Capital Management reported no remaining Maravai LifeSciences position as of Q2 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 395,547 Maravai LifeSciences shares in Q2 2024, an estimated $3.43M.
ExodusPoint Capital Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 9 quarters.
ExodusPoint Capital Management's Maravai LifeSciences position peaked at $3.43M in Q1 2024.
206 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.